IOB News

News & Media

see all

New ARVO Trustee Leopold Schmetterer

Leopold Schmetterer, Visiting Professor Translational Retinal Research at IOB, has been elected as new Board of Trustees member for Physiology/Pharmacology (PH) at ARVO, the largest and most respected eye and vision research organization in the world. 

"We are very happy to have Leopold as Visiting Professor, while keeping his affiliation in Singapore. Of note, the Singapore Eye Research Institute (SERI), where Leo serves as the research director, is one of the leading institutes in the world. His expertise in imaging, retina, glaucoma, and dry eye syndrome, and his wide network will help our teams of molecular and clinical researchers in their activities to translate findings into clinical applications and new diagnostic and therapeutic developments,” says Hendrik Scholl, IOB Director of the Clinical Research Center. Read more…

ARVO writes about Leopold Schmetterer on their website:

Dr. Schmetterer has wide-spread experience in the organization of scientific conferences for several organizations. He served on the PH program committee for ARVO and is a member of the program committee of the World Ophthalmology Congress. He served as president of EVER and organized several meetings, including the International Symposium on Ocular Pharmacology and Therapeutics. He has since been nominated as an ARVO Gold Fellow.

Schmetterer is an active PH member and ARVO attendee. He has been funded continuously over the past 20 years and is internationally recognized as an ocular pharmacology expert. His peers recognize him as someone who can represent their interests and provide strategic direction for their international organization.

Schmetterer was instrumental in the recent MANTA study, a multicenter study in Austria that assessed the efficacy of Ranibizumab and Bevacizumab in the treatment of neovascular AMD. His expertise in both clinical and basic sciences represents a combination of skills that make him an invaluable PH section representee.

In addition to his academic appointment as professor, Schmetterer serves as scientific director of the Singapore Eye Research Institute. He also serves on several editorial boards and is the recipient of a number of awards, including the Hans Goldmann Medal and the Acta Ophthalmologica Gold Medal. Schmetterer has published more than 350 articles, over 50 book chapters and edited a book entitled “Ocular Blood Flow”.

About ARVO

The Association for Research in Vision and Ophthalmology, Inc. (ARVO) was founded in 1928 in Washington, DC by a group of 73 ophthalmologists. ARVO is the largest and most respected eye and vision research organization in the world. The Association's membership today numbers about 12,000 and continues to grow. Some 45% of members reside in over 75 countries outside the U.S. The membership is multidisciplinary and consists of both clinical and basic researchers. ARVO’s mission is to advance research worldwide into understanding the visual system and preventing, treating and curing its disorders.

You are using an outdated browser. Please upgrade your browser to improve your experience and security.